Obesity Management & GLP-1 Agents
Obesity is a chronic disease, not a lifestyle choice. BMI ≥ 30 (or ≥ 27 with comorbidities) qualifies for pharmacotherapy. GLP-1 agonists and tirzepatide have transformed the field -15–25% weight loss is now achievable.
💊 Anti-Obesity Medications
| Drug | Mechanism | Weight Loss | Key Notes |
|---|---|---|---|
| Semaglutide 2.4 mg (Wegovy) PREFERRED | GLP-1 receptor agonist → ↑ satiety, ↓ appetite, delayed gastric emptying | ~15% body weight STEP 1, 2021 | Weekly SC injection. Titrate slowly over 16 weeks (nausea management). Also reduces MACE by 20% SELECT, 2023 -CV benefit independent of diabetes. Contraindicated: personal/family history of medullary thyroid carcinoma, MEN2. |
| Tirzepatide (Zepbound) MOST EFFECTIVE | Dual GIP + GLP-1 receptor agonist | ~20–25% body weight SURMOUNT-1, 2022 | Weekly SC injection. Most potent weight loss agent available. Also FDA-approved for T2DM (as Mounjaro). Same GI side effects and contraindications as semaglutide. |
| Liraglutide 3.0 mg (Saxenda) | GLP-1 RA | ~5–8% | Daily SC injection. Less effective than semaglutide but first GLP-1 approved for obesity. Being replaced by weekly options. |
| Phentermine-topiramate ER (Qsymia) | Sympathomimetic + anticonvulsant (appetite suppression) | ~8–10% | Oral daily. Avoid in uncontrolled HTN, glaucoma, hyperthyroidism. Topiramate: teratogenic (REMS program), cognitive effects, metabolic acidosis, kidney stones. |
| Naltrexone-bupropion (Contrave) | Opioid antagonist + dopamine/NE reuptake inhibitor | ~5–6% | Oral. Good for patients with food cravings/binge eating. Avoid in seizure disorders, opioid use, uncontrolled HTN. Bupropion helps with smoking cessation too. |
| Orlistat (Xenical/Alli) | Lipase inhibitor (blocks fat absorption) | ~3–5% | GI side effects (oily stools, flatulence, fecal urgency) limit tolerability. OTC version (Alli 60 mg). Least effective. |
Bariatric Surgery
- Indications: BMI ≥ 40, or BMI ≥ 35 with obesity-related comorbidity (DM, HTN, OSA, NAFLD). ADA 2026: consider for BMI ≥ 30 with uncontrolled T2DM.
- Roux-en-Y gastric bypass: ~30% excess weight loss. DM remission in 60–80%. Malabsorptive → lifelong vitamin supplementation (B12, iron, calcium, folate, vitamin D).
- Sleeve gastrectomy: most commonly performed. ~25% excess weight loss. Fewer nutritional deficiencies than RYGB. GERD may worsen.
- Most effective long-term treatment for obesity and T2DM -superior to all medications for sustained weight loss and diabetes remission.
📋 On Rounds
Pimp Questions
Why do SGLT2 inhibitors cause weight loss while sulfonylureas cause weight gain?
SGLT2 inhibitors (empagliflozin, dapagliflozin) block sodium-glucose co-transporter 2 in the proximal tubule → glycosuria (urinating out ~70g glucose/day = ~280 kcal/day). This caloric loss drives ~2–3 kg weight loss. Additionally, osmotic diuresis causes initial fluid loss. Sulfonylureas (glipizide, glimepiride) stimulate pancreatic β-cells to release insulin regardless of glucose level → hyperinsulinemia →
A patient asks: 'Will I regain the weight if I stop semaglutide?' What's the evidence?
Unfortunately, yes -most patients regain ~2/3 of lost weight within 1 year of stopping GLP-1 agonists. The STEP 1 extension trial showed that after stopping semaglutide 2.4 mg, participants regained most of the weight they had lost. This is because GLP-1 agonists work by suppressing appetite centrally and slowing gastric emptying -when the drug is removed, appetite returns to baseline.
What are the criteria for bariatric surgery referral?
BMI ≥ 40 (regardless of comorbidities) OR BMI ≥ 35 with ≥ 1 obesity-related comorbidity (T2DM, HTN, OSA, NAFLD/NASH, GERD, OA, dyslipidemia). Some guidelines now support BMI ≥ 30 with uncontrolled T2DM. Types: Roux-en-Y gastric bypass (gold standard, ~30% excess weight loss), sleeve gastrectomy (most common currently, ~25% EWL), adjustable gastric band (declining use).
What are the side effects of GLP-1 agonists that every prescriber should counsel about?
Most common (GI -dose-dependent, typically improve with slow titration): nausea (30-40%), vomiting, diarrhea, constipation, abdominal pain. Counsel: start low and titrate slowly, eat smaller meals, avoid fatty/fried foods. Serious but rare: (1) Pancreatitis: FDA warning, though causal link is debated. Stop if severe abdominal pain + elevated lipase
Clinical Examples
📋 Case 1, GLP-1 RA for Obesity with Comorbidities
Patient: 44M, BMI 38, prediabetes (A1c 6.3), OSA on CPAP, knee OA limiting exercise. Failed 6-month structured diet program (lost 3 kg, regained). Motivated for pharmacotherapy.
Key findings: Pharmacotherapy indicated: BMI ≥ 30 (or ≥ 27 with comorbidities) after failing lifestyle modification. GLP-1 RAs have the most robust evidence for weight loss + cardiometabolic benefit among anti-obesity medications.
Management:
- Semaglutide 2.4 mg SQ weekly (Wegovy), titrate from 0.25 mg over 16 weeks to minimize GI side effects STEP 1, 2021
- Continue lifestyle modification (medication + lifestyle > either alone)
- Counsel on GI side effects: nausea (most common, improves with slow titration), eat smaller meals, avoid fatty foods
- Monitor: A1c (may normalize → prevent T2DM), BP, lipids, OSA symptoms (may be able to reduce CPAP pressure)
- If weight loss ≥ 5% at 3 months: continue. If < 5%: reassess adherence, consider alternative or combination
Teaching point: Anti-obesity medications are NOT a shortcut, they correct the neurohormonal dysregulation that drives weight regain. Just as we don't shame patients for needing metformin for diabetes, we shouldn't shame them for needing semaglutide for obesity. Weight regain after stopping is expected, not failure.
📋 Case 2, Bariatric Surgery Evaluation
Patient: 52F, BMI 46, T2DM (A1c 9.4 on insulin + metformin), HTN on 3 drugs, OSA, NASH with fibrosis. Failed semaglutide (intolerable GI effects). Interested in surgical options.
Key findings: Bariatric surgery indicated: BMI ≥ 40 (or ≥ 35 with obesity-related comorbidities). This patient has multiple comorbidities likely to improve or resolve with surgery. T2DM remission rates: 60-80% after Roux-en-Y.
Management:
- Multidisciplinary bariatric evaluation: surgeon, dietitian, psychologist, medical clearance
- Roux-en-Y gastric bypass (RYGB): 25-35% total body weight loss, highest T2DM remission rate, durable results STAMPEDE, 2017
- Alternative: sleeve gastrectomy (20-25% weight loss, lower complication rate, simpler technically)
- Pre-op requirements: OSA screening, cardiac clearance, nutritional labs (B12, iron, folate, vitamin D), psych evaluation
- Lifelong supplementation post-RYGB: B12, iron, calcium + vitamin D, multivitamin (malabsorptive anatomy)
Teaching point: Bariatric surgery is the most effective treatment for severe obesity, it produces durable weight loss AND remission of T2DM, HTN, and OSA in a large proportion of patients. RYGB is superior to sleeve for T2DM remission but has higher long-term complication rates.
📋 Case 3, Tirzepatide for Obesity + T2DM
Patient: 58F, BMI 36, T2DM (A1c 8.1 on metformin), no ASCVD. Insurance covers tirzepatide for diabetes. Wants weight loss and glucose control simultaneously.
Key findings: Tirzepatide (dual GIP/GLP-1 agonist) achieves greater weight loss than semaglutide in head-to-head trials. At highest dose, mean weight loss ~20-25%, approaching surgical levels.
Management:
- Tirzepatide 2.5 mg SQ weekly → titrate q4 weeks to max 15 mg (slow titration essential for GI tolerance) SURMOUNT-1, 2022
- Continue metformin (complementary mechanism, renal protection)
- May be able to reduce or stop insulin as A1c improves
- Monitor for pancreatitis (rare but reported), gallstones (rapid weight loss increases risk)
- Discuss: weight regain occurs if medication is stopped, likely lifelong therapy needed for weight maintenance
Teaching point: Tirzepatide represents a paradigm shift, 20%+ weight loss was previously only achievable with surgery. The dual GIP/GLP-1 mechanism provides more weight loss than GLP-1 alone. Long-term data on cardiovascular outcomes is pending (SURPASS-CVOT ongoing).
📣 Sample Presentation
One-Liner
"Mr. Rodriguez is a 42-year-old with BMI 38, prediabetes (A1c 6.2), OSA on CPAP, and knee osteoarthritis. He has tried diet and exercise programs without sustained weight loss. Interested in pharmacotherapy."
Key Points to Cover on Rounds
BMI 38 with obesity-related comorbidities (prediabetes, OSA, OA). Prior weight loss attempts: commercial programs, lost 10 lbs but regained. Pharmacotherapy options discussed: (1) semaglutide 2.4 mg SQ weekly (most effective, ~15% weight loss [STEP 1, 2021]), (2) tirzepatide (dual GIP/GLP-1, ~20% weight loss [SURMOUNT-1, 2022]). Starting semaglutide 0.25 mg weekly, uptitrate monthly to 2.4 mg. Counseling: medication is one component alongside lifestyle (goal: 150 min/week moderate exercise, dietary changes). Insurance coverage checked. Bariatric surgery discussed as alternative (BMI ≥35 + comorbidities = eligible). Plan: monthly follow-up for dose titration, weight, and A1c monitoring.
🧪 Workup
Workup -Obesity
1. Measure and stage
- BMI plus waist circumference. BMI alone misses central adiposity, which is what carries the cardiometabolic risk. Measure both.
- Use lower BMI thresholds in South and East Asian patients, in whom metabolic risk begins at a lower BMI, so the standard cut-points under-call disease.
- Stage by complications, not by weight alone. The presence of a weight-related complication, rather than the number itself, is what justifies escalating therapy.
2. Screen for the complications that change management
- Dysglycemia: A1c or fasting glucose. Prediabetes strengthens the case for a GLP-1 based agent.
- Lipids and blood pressure, with cardiovascular risk assessment.
- Liver: ALT and AST, with a fibrosis score such as FIB-4. Metabolic dysfunction-associated steatotic liver disease is common and usually silent.
- Obstructive sleep apnea: screen with STOP-BANG. It is underdiagnosed, and treating it improves the symptoms patients often attribute to weight alone.
- Mental health and eating pattern, including binge eating, which changes the therapeutic approach.
3. Exclude secondary and iatrogenic causes
- TSH for hypothyroidism; consider Cushing syndrome where there are suggestive features, since neither is common but both are treatable.
- Review the medication list for weight-promoting drugs: several antipsychotics, some antidepressants, glucocorticoids, insulin and sulfonylureas, and certain antiepileptics. Substituting a weight-neutral alternative is often the highest-yield intervention available.
Before prescribing a GLP-1 receptor agonist, check specifically for: a personal or family history of medullary thyroid carcinoma or MEN2, which is a contraindication; a history of pancreatitis; gastroparesis or significant gastrointestinal disease; and pregnancy or plans to conceive. Ask these before the prescription, not after the first side effect.
💊 Medications
Medications
Anti-obesity medication details (GLP-1 agonists, semaglutide, liraglutide; dual GIP/GLP-1, tirzepatide; phentermine/topiramate; naltrexone/bupropion; orlistat) with evidence-based dosing, weight-loss percentages, and trial citations (STEP 1, SURMOUNT-1, SELECT, SCALE) are in the Management tab.
⚡ Summary
Summary
Treat It as a Chronic Disease
Obesity is a chronic relapsing disease, not a lifestyle choice or a failure of willpower. BMI 30 or above, or 27 or above with a weight-related comorbidity, qualifies for pharmacotherapy alongside lifestyle intervention. Weight regain on stopping treatment is the expected biology, not relapse of bad behavior.
Stage Beyond BMI
BMI misclassifies the muscular and the sarcopenic, and it performs differently across ethnic groups, with lower thresholds appropriate in South Asian populations. Add waist circumference and, above all, the complications: type 2 diabetes, MASLD, obstructive sleep apnea, osteoarthritis, hypertension, dyslipidemia and infertility. The complications, not the number, determine urgency.
Know What the New Agents Achieve
Semaglutide gives roughly 15% weight loss and tirzepatide, a dual GIP/GLP-1 agonist, roughly 20 to 25%, which is a different order of magnitude from older agents. Semaglutide also reduces major cardiovascular events in patients with established cardiovascular disease and obesity without diabetes (SELECT), so this is no longer only a weight intervention.
Titrate Slowly and Manage the GI Effects
Nausea, vomiting, diarrhea and constipation are dose-related and are the main reason patients stop. Escalate on schedule, not faster, and hold at a tolerated dose. Advise smaller meals and less fat. Most GI effects settle over weeks, and warning the patient in advance is what keeps them on treatment.
Screen Before the First Dose
Personal or family history of medullary thyroid carcinoma or MEN2 is a contraindication. Also check for a history of pancreatitis, gastroparesis or significant gastrointestinal disease, and active gallbladder disease. Rapid weight loss itself increases gallstone risk, so the association is partly a consequence of success.
Adjust the Other Diabetes Drugs
Reduce insulin and stop or reduce sulfonylureas when starting a GLP-1 agonist, because the combination causes hypoglycemia. GLP-1 agonists alone rarely cause hypoglycemia, since their insulin effect is glucose-dependent. Also flag the delayed gastric emptying before elective procedures requiring sedation.
Preserve Muscle and Plan for Maintenance
A substantial fraction of the weight lost is lean mass, so resistance exercise and adequate protein intake are part of the prescription rather than optional advice. Weight is regained when the drug stops (STEP 4), so frame treatment as ongoing, and discuss cost and coverage honestly at the outset, since that is what most often ends therapy.
Know When Surgery Is the Better Answer
BMI 40 or above, or 35 or above with comorbidity, and increasingly BMI 30 to 35 with poorly controlled type 2 diabetes. Bariatric surgery produces the largest and most durable weight loss and reduces mortality, with high rates of diabetes remission. It commits the patient to lifelong micronutrient supplementation and monitoring for B12, iron, calcium, vitamin D and thiamine, and to a real perioperative and long-term complication profile.
🔍 Overview
Overview -Obesity Management & GLP-1 Agents
See the tabs above for the complete clinical reference: Workup, Management, Medications, Monitoring, Rounds, Summary, and One Pager.
📄 One Pager
Text version
Endocrine / Primary Care · One Pager
Obesity
BMI ≥ 30 = obesity. GLP-1 RAs are transformative (~15-20% weight loss). Bariatric surgery for BMI ≥ 40 or ≥ 35 + comorbidity. Lifestyle is foundation but insufficient alone for severe obesity.
Classification
BMI 25-29.9 = overweight. 30-34.9 = class I obesity. 35-39.9 = class II. ≥ 40 = class III. Screen for comorbidities: OSA, NAFLD, T2DM, HTN, dyslipidemia.
Pharmacotherapy
Semaglutide 2.4 mg SQ weekly (~15% weight loss [STEP 1, 2021]). Tirzepatide (dual GIP/GLP-1, ~20% [SURMOUNT-1, 2022]). Titrate slowly to minimize GI side effects. Lifestyle (150 min/week exercise + dietary changes) is always the foundation.
Bariatric Surgery
BMI ≥ 40 or ≥ 35 + comorbidity. Sleeve gastrectomy (most common). RYGB (gold standard). T2DM remission 60-80%. 50-70% excess weight loss. Lifelong vitamin monitoring required.
Key Drugs
Semaglutide0.25 → 2.4 mg SQ weekly
Tirzepatide2.5 → 15 mg SQ weekly
Phentermine-topiramate3.75/23 → 15/92 mg daily
Lifestyle150 min/week exercise + caloric deficit
Related Topics
Outpatient Diabetes ManagementOutpatient Lipid ManagementPreventive Care & ScreeningSmoking Cessation